One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
TELA Bio, Inc.
TELA · NGM · Healthcare · Medical Devices
Current price
$0.80
52-week range
$0.50 - $1.50
Market cap
$36.11M
Balance sheet
Distressed
-6.44x Concerning
Net debt $27.49M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
TELA Bio, Inc.
TELA Bio makes medical devices, primarily for hernia repair and reconstructive surgery, that help patients' bodies heal and rebuild. Their main money source is selling these specialized products to hospitals and surgeons. This matters because it shows how well their unique medical solutions are being adopted by doctors.
How the company got here
TELA Bio was founded in 2012 with a mission to improve surgical outcomes by helping patients' bodies heal themselves. The company recognized a need for better materials to support soft tissues during reconstruction procedures, especially for hernias and abdominal wall repairs. After years of research and development, TELA Bio brought its innovative OviTex products to market, aiming to provide a more natural and effective solution than existing options. The company is headquartered in Malvern, Pennsylvania, and has focused on building a direct sales force to reach surgeons across the United States.
What it actually does
TELA Bio develops and sells medical devices designed to help surgeons repair damaged or weakened soft tissues in the body. Think of it like providing a special kind of internal scaffolding that encourages the patient's own tissues to grow and heal. Their main products are made from a material called OviTex, which is designed to reinforce these repairs. These products are used in various surgical procedures, primarily to fix hernias and reconstruct abdominal walls, helping patients recover more effectively.
Hernia Repair and Abdominal Wall Reconstruction
This is TELA Bio's primary business line, focusing on products that help surgeons fix hernias and rebuild abdominal walls. A hernia occurs when an organ pushes through a weak spot in the surrounding muscle or tissue, and abdominal wall reconstruction is needed for more complex cases. TELA Bio's OviTex products in this area act as a reinforcement, providing support while the patient's own tissue integrates with the implant. This segment represents the core of the company's revenue and strategic focus, as it addresses a significant surgical need.
Plastic and Reconstructive Surgery
TELA Bio also offers specialized OviTex products tailored for plastic and reconstructive surgery. These applications go beyond hernia repair and can include procedures where soft tissue support is crucial for aesthetic or functional restoration. While this segment may be smaller than the hernia repair business, it represents an important area for growth and diversification, allowing the company to leverage its technology in a broader surgical market.
What management is betting on now
TELA Bio's management is focused on expanding the adoption of its OviTex products within the surgical community. A key priority is to demonstrate the clinical and economic benefits of their technology to surgeons and hospitals, encouraging them to choose TELA Bio's solutions. They are also likely investing in further research and development to enhance their product offerings and explore new applications for their soft-tissue reconstruction technology. The company's strategy hinges on proving that their approach leads to better patient outcomes and a more efficient healthcare process.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-7.79M
FY2025 Q1
$-9.76M
FY2025 Q2
$-8.02M
FY2025 Q3
$-5.93M
FY2025 Q4
$-4.96M
FY2026 Q1
$-11.29M
FY2026 Q2
$-9.44M
FY2026 Q3
$-8.70M
Revenue
$18.96M
Net income
$-9.30M
Diluted EPS
-0.16
Operating cash flow
$-8.69M
Free cash flow
$-8.70M
Fetching…
Sources
Revenue
$19.29M
Net income
$-11.26M
Diluted EPS
-0.20
Operating cash flow
$-9.38M
Free cash flow
$-9.44M
Fetching…
Sources
Revenue
$19.06M
Net income
$-12.27M
Diluted EPS
-0.21
Operating cash flow
$-11.17M
Free cash flow
$-11.29M
Fetching…
Sources
Revenue
$20.87M
Net income
$-9.04M
Diluted EPS
-0.17
Operating cash flow
$-4.87M
Free cash flow
$-4.96M
Fetching…
Sources
Revenue
$20.69M
Net income
$-8.60M
Diluted EPS
-0.19
Operating cash flow
$-5.72M
Free cash flow
$-5.93M
Fetching…
Sources
Revenue
$20.20M
Net income
$-9.92M
Diluted EPS
-0.22
Operating cash flow
$-7.91M
Free cash flow
$-8.02M
Fetching…
Sources
Revenue
$18.52M
Net income
$-11.26M
Diluted EPS
-0.25
Operating cash flow
$-9.72M
Free cash flow
$-9.76M
Fetching…
Sources
Revenue
$17.65M
Net income
$-9.21M
Diluted EPS
-0.17
Operating cash flow
$-7.53M
Free cash flow
$-7.79M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.80
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $27.5M. Interest coverage -6.4x.
Net debt
$27.49M
Interest coverage
-6.44x
TELA Bio, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
TELA
BASELINE
TELA Bio, Inc.
Total debt $57.92M Interest coverage -6.44x This is the baseline the peer rows are being compared against.
Total debt $64.52M Interest coverage 36.18x This peer still has a real interest-payment cushion, while TELA does not.
Total debt $0.00 Interest coverage 63.51x This peer still has a real interest-payment cushion, while TELA does not.
Total debt $2.00B Interest coverage 0.21x This peer still has a real interest-payment cushion, while TELA does not.
Total debt $407.03M Interest coverage 1.01x This peer still has a real interest-payment cushion, while TELA does not.
What you should know
The case for and against TELA
0 Rewards
1 Risk
Rewards
Risks
-
Insider ownership is only 7.2% (peer median: 9.3%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.76x
P/B
-2.26x
P/S
0.45x
EV/EBITDA
-1.92x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
68.3%
Operating margin
-48.1%
Net margin
-51.5%
ROE
—
ROA
-33.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
2.99x
Quick ratio
2.20x
Total debt
$57.92M
Total cash
$30.42M
Growth
How the business has been compounding
Revenue TTM
$78.18M
Revenue 5Y CAGR
28.5%
EPS TTM
-0.77
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-34.11M
Free CF TTM
$-28.67M
FCF margin
-36.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—